Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 2, 2011, Pages 156-164

  Hu, Cheng En ^a   Gan, Jun ^a   Zhang, Rui Dong ^b   Cheng, Yan Ru ^a   Huang, Guang Jian ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI CHILDREN S MEDICAL CENTER   (China)

Author keywords

Dendritic cell; hepatocellular carcinoma; myeloid derived suppressor cells

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; MYELOID DIFFERENTIATION FACTOR 88;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CANCER TISSUE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; IMMUNOREGULATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LYMPH NODE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SPLEEN; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELLS; INTERLEUKIN-10; INTERLEUKIN-12; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; MYELOID CELLS; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

EID: 79951756351     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.516450     Document Type: Article

References (36)

1. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-19. (Pubitemid 38402113)
2. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188:341-50. (Pubitemid 28357762)
3. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59. (Pubitemid 41400849)
4. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009;49:124-32.
5. Sheng XL, Zhang H. In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells. World J Gastroenterol 2007;13:5944-50. (Pubitemid 350148512)
6. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, Fukuzawa Y, Yoshioka K. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 2000;15:431-6. (Pubitemid 30262212)
7. Caux C, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 1995;16:2-4.
8. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, Michitaka K, et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 2000;148:49-57. (Pubitemid 30012128)
9. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16: 53-65. (Pubitemid 43139709)
10. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)FOXP3(+) T cells. Gastroenterology 2008;135:234-43. (Pubitemid 351899008)
11. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8. (Pubitemid 35363648)
12. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-92. (Pubitemid 41361997)
13. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52. (Pubitemid 39620069)
14. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222: 162-79. (Pubitemid 351430364)
15. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR, Zhang HG. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007;109:4336-42. (Pubitemid 46743401)
16. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11B+GR1+ myeloid cells. Nat Biotechnol 2007;25:911-20. (Pubitemid 47236916)
17. Seandel M, Butler J, Lyden D, Rafii S. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. Cancer Cell 2008;13:181-3. (Pubitemid 351318378)
18. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducingmyeloid-derived suppressor cell function. J Exp Med 2006;203:2691-702. (Pubitemid 44833345)
19. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloidderived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439-49.
20. Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, et al. Myeloid-derived suppressor cells in mammary tumor progression in FVB neu transgenic mice. Cancer Immunol Immunother 2010;59:47-62.
21. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKP30 receptor. Hepatology 2009;50: 799-807.
22. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005;174:636-45. (Pubitemid 40094255)
23. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702.
24. Zhang JK, Sun JL, Chen HB, Zeng Y, Qu YJ. Influence of granulocyte macrophage colony stimulating factor and tumor necrosis factor on anti-hepatoma activities of human dendritic cells. World J Gastroenterol 2000;6:718-20.
25. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand- Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179:977-83.
26. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand- Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through toll-like receptor 4. J Leukoc Biol 2009;85:996-1004.
27. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49.
28. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66. (Pubitemid 30305068)
29. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9: 961-8. (Pubitemid 36323698)
30. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004;92: 13-27. (Pubitemid 39458111)
31. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003;63: 2150-7. (Pubitemid 36538620)
32. Almand B, Clark JI, Nikitina E, Van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89. (Pubitemid 32038493)
33. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of granulocytemacrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728-37. (Pubitemid 29314923)
34. Brys L, Beschin A, Raes G, Ghassabeh GH, Noel W, Brandt J, et al. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol 2005;174:6095-104. (Pubitemid 40663798)
35. Greifenberg V, Ribechini E, Rossner S, Lutz MB. Myeloidderived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009;39:2865-76.
36. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3: 133-46. (Pubitemid 37328691)